Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial

医学 内科学 肺癌 肺 不利影响 安全概况 临床研究阶段 胃肠病学 肿瘤科 临床试验 外科 病理 小细胞癌 小学(天文学) 相(物质) 入射(几何) 细胞 癌症研究
作者
Charles M. Rudin,Melissa Lynne Johnson,Luis G Paz-Ares,Makoto Nishio,Christine L. Hann,Nicolas Girard,Pedro Rocha,Hidetoshi Hayashi,Tetsuya Sakai,Yu Jung Kim,Haichuan Hu,Meng Qian,Jasmeet Chadha Singh,Juliette Godard,Mei Tang,Myung‐Ju Ahn
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:44 (4): 261-273 被引量:56
标识
DOI:10.1200/jco-25-02142
摘要

PURPOSE: Treatment options for patients with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) are limited. This phase II trial evaluated the efficacy and safety of ifinatamab deruxtecan (I-DXd), a B7 homolog 3-directed antibody-drug conjugate, in patients with previously treated ES-SCLC. METHODS: Patients were randomly assigned to receive I-DXd 8 or 12 mg/kg intravenously once every 3 weeks in part 1 (dose optimization) and received I-DXd 12 mg/kg in part 2 (extension). The primary end point was objective response rate (ORR) by blinded independent central review per RECIST, version 1.1. RESULTS: Overall, 183 patients received I-DXd: 88 in part 1 (8 mg/kg, n = 46; 12 mg/kg, n = 42) and 95 in part 2. The median number of previous lines of treatment was two. In the total 12-mg/kg group from parts 1 and 2 (n = 137), the confirmed ORR was 48.2% (95% CI, 39.6 to 56.9), median duration of response was 5.3 (95% CI, 4.0 to 6.5) months, median time to response was 1.4 (range, 1.0-8.1) months, median progression-free survival was 4.9 (95% CI, 4.2 to 5.5) months, and the 9-month overall survival estimate was 59.1%. Any-grade treatment-related adverse events (TRAEs) occurred in 89.8% of patients (grade ≥3, 36.5%). The most common TRAEs were nausea (43.1%), anemia (34.3%), and neutropenia (34.3%). TRAEs associated with treatment discontinuation and death were reported in 9.5% and 4.4% of patients, respectively. Treatment-related interstitial lung disease (ILD) as determined by the ILD adjudication committee was reported in 12.4% of patients (grade ≥3, 4.4%). CONCLUSION: I-DXd 12 mg/kg once every 3 weeks showed promising efficacy in patients with previously treated ES-SCLC. The observed safety profile was consistent with previous reports, with no new safety signals identified.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
张点心关注了科研通微信公众号
刚刚
火星上若云完成签到,获得积分10
1秒前
1秒前
烟花的应助被tutu采纳,获得10
1秒前
1秒前
忆寒完成签到,获得积分10
1秒前
丘比特的应助被yize采纳,获得10
1秒前
2秒前
3秒前
3秒前
dscsacas发布了新的文献求助10
4秒前
105完成签到,获得积分10
5秒前
5秒前
5秒前
阿墩的应助被文若采纳,获得10
5秒前
wjt完成签到,获得积分10
5秒前
LIU发布了新的文献求助10
6秒前
明理的访风完成签到,获得积分10
6秒前
赘婿的应助被FGGFGGU采纳,获得30
6秒前
agrlook完成签到,获得积分10
6秒前
荼蘼发布了新的文献求助10
7秒前
7秒前
7秒前
科研通AI6.4的应助被着急的焦采纳,获得10
7秒前
8秒前
33发布了新的文献求助10
8秒前
8秒前
万能图书馆的应助被kbyang采纳,获得10
9秒前
9秒前
隐形曼青的应助被kbyang采纳,获得10
11秒前
汉堡包的应助被咸鱼大帝采纳,获得10
11秒前
大个的应助被霸气的啤酒采纳,获得20
11秒前
11秒前
啦啦啦啦完成签到 ,获得积分0
12秒前
所所的应助被kbyang采纳,获得10
12秒前
Eli发布了新的文献求助10
12秒前
12秒前
激动的项链完成签到,获得积分10
12秒前
漏网之鱼完成签到,获得积分10
13秒前
砥砺前行完成签到 ,获得积分10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175157
求助须知:如何正确求助?哪些是违规求助? 9566975
关于积分的说明 21789458
捐赠科研通 7769647
什么是DOI,文献DOI怎么找? 3431836
关于科研通互助平台的介绍 2556078
邀请新用户注册赠送积分活动 2477241